RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:16:00Z
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Wed 19 Feb 25, 01:53 PMTop Analyst Reports for Home Depot, Booking & Eaton
Tue 18 Feb 25, 09:52 PMWhy AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now
Mon 17 Feb 25, 07:48 AMAbbVie Full Year 2024 Earnings: EPS Misses Expectations
Sun 16 Feb 25, 01:16 PMPharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Fri 14 Feb 25, 01:03 PMAbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Fri 14 Feb 25, 12:40 PMJohn Rogers' Strategic Moves: A Closer Look at Royal Caribbean Group's Impact
Fri 14 Feb 25, 12:03 PMAbbVie Declares Quarterly Dividend
Thu 13 Feb 25, 04:57 PMAbbVie Inc. (ABBV): Among Lee Munder Capital Group’s Top Stock Picks
Thu 13 Feb 25, 03:48 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 13477.00M | 12989.00M | 3398.00M | 8426.00M | 5197.00M |
| Minority interest | -9.00000M | -7.00000M | 6.00M | 21.00M | 21.00M |
| Net income | 11836.00M | 11542.00M | 4616.00M | 7882.00M | 5687.00M |
| Selling general administrative | 15260.00M | 12349.00M | 11299.00M | 6942.00M | 7399.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 40640.00M | 38751.00M | 30417.00M | 25827.00M | 25035.00M |
| Reconciled depreciation | 8467.00M | 8521.00M | 6471.00M | 2017.00M | 1765.00M |
| Ebit | 18117.00M | 17924.00M | 476.00M | 12983.00M | 6383.00M |
| Ebitda | 26584.00M | 26445.00M | 6947.00M | 13795.00M | 8148.00M |
| Depreciation and amortization | 8467.00M | 8521.00M | 6471.00M | 812.00M | 1765.00M |
| Non operating income net other | -2596.00000M | -2551.00000M | -5685.00000M | -3048.00000M | -42.00000M |
| Operating income | 18117.00M | 17924.00M | 476.00M | 12983.00M | 6383.00M |
| Other operating expenses | 39240.00M | 37311.00M | 33243.00M | 19898.00M | 25946.00M |
| Interest expense | 2230.00M | 2384.00M | 2280.00M | 1509.00M | 1144.00M |
| Tax provision | 1632.00M | 1440.00M | -1224.00000M | 544.00M | -490.00000M |
| Interest income | 186.00M | 39.00M | 174.00M | 275.00M | 204.00M |
| Net interest income | -2044.00000M | -2384.00000M | -2280.00000M | -1509.00000M | -1144.00000M |
| Extraordinary items | - | - | - | - | -86.00000M |
| Non recurring | 697.00M | 962.00M | 1198.00M | 385.00M | 424.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 1632.00M | 1440.00M | -1224.00000M | 544.00M | -490.00000M |
| Total revenue | 58054.00M | 56197.00M | 45804.00M | 33266.00M | 32753.00M |
| Total operating expenses | 21826.00M | 19865.00M | 17856.00M | 12459.00M | 18228.00M |
| Cost of revenue | 17414.00M | 17446.00M | 15387.00M | 7439.00M | 7718.00M |
| Total other income expense net | -3293.00000M | -3513.00000M | 2922.00M | -4557.00000M | -466.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 11845.00M | 11549.00M | 4622.00M | 7882.00M | 5687.00M |
| Net income applicable to common shares | 11836.00M | 11542.00M | 4616.00M | 7882.00M | 5687.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 134711.00M | 138805.00M | 146529.00M | 150565.00M | 89115.00M |
| Intangible assets | 55610.00M | 67439.00M | 75951.00M | 82876.00M | 18649.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 4932.00M | 4401.00M | 4993.00M | 3562.00M | 2354.00M |
| Total liab | 124314.00M | 121518.00M | 131093.00M | 137468.00M | 97287.00M |
| Total stockholder equity | 10360.00M | 17254.00M | 15408.00M | 13076.00M | -8172.00000M |
| Deferred long term liab | - | 2190.00M | 3009.00M | 3646.00M | 1130.00M |
| Other current liab | 26962.00M | 22468.00M | 19817.00M | 17883.00M | 10380.00M |
| Common stock | 18.00M | 18.00M | 18.00M | 18.00M | 18.00M |
| Capital stock | 18.00M | 18.00M | 18.00M | 18.00M | 18.00M |
| Retained earnings | -1000.00000M | 4784.00M | 3127.00M | 1055.00M | 4717.00M |
| Other liab | - | 31716.00M | 30982.00M | 30401.00M | 18476.00M |
| Good will | 32293.00M | 32156.00M | 32379.00M | 33124.00M | 15604.00M |
| Other assets | - | 4834.00M | 4081.00M | 5144.00M | 1913.00M |
| Cash | 12814.00M | 9201.00M | 9746.00M | 8449.00M | 39924.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 37841.00M | 29538.00M | 35194.00M | 28661.00M | 15585.00M |
| Current deferred revenue | -3688.00000M | - | - | - | - |
| Net debt | 46571.00M | 54070.00M | 66938.00M | 77607.00M | 26804.00M |
| Short term debt | 7191.00M | 4136.00M | 12495.00M | 8502.00M | 3753.00M |
| Short long term debt | 7191.00M | 4136.00M | 12495.00M | 8502.00M | 3753.00M |
| Short long term debt total | 59385.00M | 63271.00M | 76684.00M | 86056.00M | 66728.00M |
| Other stockholder equity | 13647.00M | 14651.00M | 15162.00M | 15120.00M | -9311.00000M |
| Property plant equipment | - | 4935.00M | 5110.00M | 5248.00M | 2962.00M |
| Total current assets | 33002.00M | 28463.00M | 27928.00M | 24173.00M | 49519.00M |
| Long term investments | 304.00M | 241.00M | 277.00M | 293.00M | 93.00M |
| Net tangible assets | - | -82341.00000M | -96202.00000M | -102924.00000M | -42425.00000M |
| Short term investments | 2.00M | 28.00M | 84.00M | 30.00M | 0.00000M |
| Net receivables | 11155.00M | 11254.00M | 9977.00M | 8822.00M | 5428.00M |
| Long term debt | 52194.00M | 59135.00M | 64189.00M | 77554.00M | 62975.00M |
| Inventory | 4099.00M | 3579.00M | 3128.00M | 3310.00M | 1813.00M |
| Accounts payable | 3688.00M | 2934.00M | 2882.00M | 2276.00M | 1452.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 37.00M | 33.00M | 28.00M | 21.00M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2305.00000M | -2199.00000M | -2899.00000M | -3117.00000M | -3596.00000M |
| Additional paid in capital | 20180.00M | - | - | - | - |
| Common stock total equity | - | 18.00M | 18.00M | 18.00M | 18.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 4784.00M | 3127.00M | 1055.00M | 4717.00M |
| Treasury stock | -6533.00000M | -4594.00000M | -3143.00000M | -2264.00000M | -24504.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8513.00M | 3381.00M | 1875.00M | 1205.00M | 1158.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 101709.00M | 110342.00M | 118601.00M | 126392.00M | 39596.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 59135.00M | 64189.00M | 77554.00M | 62975.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -447.00000M | -1398.00000M | 114.00M | 981.00M | -368.00000M |
| Change to liabilities | 2147.00M | 338.00M | 941.00M | -1121.00000M | 190.00M |
| Total cashflows from investing activities | -623.00000M | -2344.00000M | -37557.00000M | 596.00M | -1006.00000M |
| Net borrowings | -12433.00000M | -8414.00000M | -2703.00000M | 25823.00M | 3189.00M |
| Total cash from financing activities | -24803.00000M | -19039.00000M | -11501.00000M | 18708.00M | -14396.00000M |
| Change to operating activities | -264.00000M | -197.00000M | 134.00M | 97.00M | -499.00000M |
| Net income | 11845.00M | 11549.00M | 4622.00M | 7882.00M | 5687.00M |
| Change in cash | -545.00000M | 1297.00M | -31475.00000M | 32635.00M | -2014.00000M |
| Begin period cash flow | 9746.00M | 8449.00M | 39924.00M | 7289.00M | 9303.00M |
| End period cash flow | 9201.00M | 9746.00M | 8449.00M | 39924.00M | 7289.00M |
| Total cash from operating activities | 24943.00M | 22777.00M | 17588.00M | 13324.00M | 13427.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 8467.00M | 8521.00M | 6471.00M | 2017.00M | 1765.00M |
| Other cashflows from investing activities | 519.00M | -159.00000M | -36873.00000M | 167.00M | 167.00M |
| Dividends paid | -10043.00000M | -9261.00000M | -7716.00000M | -6366.00000M | -5580.00000M |
| Change to inventory | -686.00000M | -142.00000M | -40.00000M | -231.00000M | -226.00000M |
| Change to account receivables | -1455.00000M | -1321.00000M | -929.00000M | -74.00000M | -591.00000M |
| Sale purchase of stock | -1487.00000M | -934.00000M | -978.00000M | -629.00000M | -12014.00000M |
| Other cashflows from financing activities | 1160.00M | -674.00000M | -333.00000M | -552.00000M | -104.00000M |
| Change to netincome | 2646.00M | 4029.00M | 6389.00M | 4754.00M | 6677.00M |
| Capital expenditures | 695.00M | 787.00M | 798.00M | 552.00M | 638.00M |
| Change receivables | -1455.00000M | -1321.00000M | -929.00000M | -74.00000M | -591.00000M |
| Cash flows other operating | 1979.00M | -197.00000M | 134.00M | 97.00M | -75.00000M |
| Exchange rate changes | - | -97.00000M | -5.00000M | 7.00M | -39.00000M |
| Cash and cash equivalents changes | -483.00000M | 1297.00M | -31475.00000M | 32635.00M | -2014.00000M |
| Change in working capital | -258.00000M | -1322.00000M | 106.00M | -1329.00000M | -1126.00000M |
| Stock based compensation | 671.00M | 692.00M | 753.00M | 430.00M | 421.00M |
| Other non cash items | 6149.00M | 4235.00M | 7961.00M | 3624.00M | 6256.00M |
| Free cash flow | 24248.00M | 21990.00M | 16790.00M | 12772.00M | 12789.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ABBV AbbVie Inc |
2.65 1.34% | 200.00 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| LLY Eli Lilly and Company |
5.62 0.65% | 872.67 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
1.67 1.06% | 159.56 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| MRK Merck & Company Inc |
1.50 1.75% | 87.09 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| AZN AstraZeneca PLC ADR |
0.78 1.06% | 74.59 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 1954 |
| Mr. Robert A. Michael | Vice Chairman & Pres | 1970 |
| Ms. Laura J. Schumacher | Vice Chairman of External Affairs & Chief Legal Officer | 1963 |
| Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer | 1969 |
| Mr. Scott T. Reents | Exec. VP & CFO | 1967 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP of Operations | 1963 |
| Dr. Thomas J. Hudson | Sr. VP of R&D and Chief Scientific Officer | 1962 |
| Ms. Elizabeth Shea | VP of Investor Relations | NA |
| Mr. Perry C. Siatis | Exec. VP, Gen. Counsel & Sec. | NA |
| Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...